Halcion Australia - English - Department of Health (Therapeutic Goods Administration)

halcion

pfizer australia pty ltd - triazolam -

ENERGIZE-ER ELECTROLYTE REPLACER WITH VITAMIN C AND VITAMIN E FOR GREYHOUNDS Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

energize-er electrolyte replacer with vitamin c and vitamin e for greyhounds

sykes vet (international) pty. ltd. - maltrodextrin; citric acid; potassium chloride; magnesium sulfate; sodium chloride; sodium citrate; sodium sulfate; vitamin c = ascorbic acid; vitamin e - oral powder, pre-mix - maltrodextrin polysaccharide active 470.86 g; citric acid acid-general active 4.2 g; potassium chloride mineral-potassium active 500.0 g; magnesium sulfate mineral-magnesium active 4.2 g; sodium chloride mineral-sodium-salt active 1.24 g; sodium citrate mineral-sodium-salt active 6.6 g; sodium sulfate mineral-sodium active 1.0 g; vitamin c = ascorbic acid vitamin-c active 1.5 g; vitamin e vitamin-e active 3000.0 i.u. - nutrition & metabolism - dog - greyhound | racing greyhound - electrolyte replacement

Inza Australia - English - Department of Health (Therapeutic Goods Administration)

inza

alphapharm pty ltd - naproxen -

Potassium chloride 30mmol in 5% Glucose New Zealand - English - Medsafe (Medicines Safety Authority)

potassium chloride 30mmol in 5% glucose

baxter healthcare ltd - glucose 5%; potassium chloride 0.224% - solution for infusion - 30 mmol/l - active: glucose 5% potassium chloride 0.224% - potassium chloride and glucose iv infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of potassium and chloride ion concentrations. this is also an alternative route of administration for patients who are unable to take potassium orally or if hypokalaemia is severe. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Potassium Chloride 20mmol in 5% Glucose New Zealand - English - Medsafe (Medicines Safety Authority)

potassium chloride 20mmol in 5% glucose

baxter healthcare ltd - glucose 5%; potassium chloride 0.15% - solution for infusion - 20 mmol/l - active: glucose 5% potassium chloride 0.15% - potassium chloride and glucose iv infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of potassium and chloride ion concentrations. this is also an alternative route of administration for patients who are unable to take potassium orally or if hypokalaemia is severe. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Potassium Chloride 30mmol in 4% Glucose and 0.18% Sodium Chloride (Baxter) New Zealand - English - Medsafe (Medicines Safety Authority)

potassium chloride 30mmol in 4% glucose and 0.18% sodium chloride (baxter)

baxter healthcare ltd - glucose 40 g/l; potassium chloride 2.24 g/l; sodium chloride 1.8 g/l - solution for infusion - 30 mmol/l - active: glucose 40 g/l potassium chloride 2.24 g/l sodium chloride 1.8 g/l - for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the medicine is compatible with this solution.

Potassium Chloride 20mmol in 4% Glucose and 0.18% Sodium Chloride New Zealand - English - Medsafe (Medicines Safety Authority)

potassium chloride 20mmol in 4% glucose and 0.18% sodium chloride

baxter healthcare ltd - glucose 40 g/l; potassium chloride 1.5 g/l; sodium chloride 1.8 g/l - solution for infusion - active: glucose 40 g/l potassium chloride 1.5 g/l sodium chloride 1.8 g/l - for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the medicine is compatible with this solution.

CYTOSAR 500 mg INJECTION South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

cytosar 500 mg injection

pfizer laboratories (pty) ltd - injection - see ingredients - each vial contains cytarabine 500 mg

CYTOSAR 1000 mg INJECTION South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

cytosar 1000 mg injection

pfizer laboratories (pty) ltd - injection - see ingredients - each vial contains cytarabine 1000 mg

Menactra New Zealand - English - Medsafe (Medicines Safety Authority)

menactra

pharmacy retailing (nz) ltd t/a healthcare logistics - meningococcal polysaccharide 48ug (4 µg of each of groups a, c, y & w-135, each separately conjugated to diphtheria toxoid, 48 µg total) - solution for injection - 4 µg each/0.5 ml - active: meningococcal polysaccharide 48ug (4 µg of each of groups a, c, y & w-135, each separately conjugated to diphtheria toxoid, 48 µg total) excipient: dibasic sodium phosphate monobasic sodium phosphate sodium chloride water for injection - menactra vaccine is indicated for active immunisation in individuals from 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by n. meningitidis serogroups a, c, y and w-135. menactra vaccine is not indicated for the prevention of meningitis caused by other microorganisms or for the prevention of invasive meningococcal disease caused by n meningitidis serogroup b. menactra vaccine is not indicated for treatment of meningococcal infections. menactra vaccine is not indicated for immunisation against diphtheria.